ReviewInflammation2021
The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia.
Review in Inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.Cancer metastasis reviews · 2026Review
- Pro-inflammatory cytokine-driven molecular signaling in skeletal muscle during cancer cachexia.Biochemical Society transactions · 2026Review
- Cancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.Cell death & disease · 2026Article
- Tumor-muscle communication in cancer-associated cachexia (Review).Oncology letters · 2026Review
- Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization.Frontiers in immunology · 2026Observational
- The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies.Medical oncology (Northwood, London, England) · 2025Review
- Identifying the heterogeneity of self-advocacy in Chinese patients with breast cancer using latent profile analysis and symptom networks.Asia-Pacific journal of oncology nursing · 2025Article
- Inhibition of NLRP3 inflammasome activation alleviated liver injury and wasting effect in tumor-bearing mice.Scientific reports · 2025Article
- Associations of systemic immune-inflammation index, product of platelet, and neutrophil count, with the pathological grade of bladder cancer.The Canadian journal of urology · 2025Article
- Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.Cancer discovery · 2025Review
- Effect of IL-1β on NSCLC-Derived Small Extracellular Vesicles as Actors in Mediating Cancer Progression and Evading Immune System.International journal of molecular sciences · 2025Article
- Article
- PD-1 Inhibitor Aggravate Irradiation-Induced Myocardial Fibrosis by Regulating TGF-β1/Smads Signaling Pathway via GSDMD-Mediated Pyroptosis.Inflammation · 2025Article
- Correlation Analysis of Pyroptosis-Related Genes CASP1, NLRP3, AIM2, and NLRP1 With Lung Adenocarcinoma.International journal of genomics · 2025Article
- Article
- Cancer cachexia: multilevel metabolic dysfunction.Nature metabolism · 2024Review
- Increased Myocardial MAO-A, Atrogin-1, and IL-1β Expression in Transgenic Mice with Pancreatic Carcinoma-Benefit of MAO-A Inhibition for Cardiac Cachexia.Biomedicines · 2024Article
- Understanding cachexia and its impact on lung cancer and beyond.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Treatment of cancer cachexia remains an unmet need. The host-tumour interface and the resulting sequestration of the pro-inflammatory cytokine Il-1β is critical in cachexia development. Neuroinflammation mediated via IL-1β through the hypothalamic pituitary axis results in increased muscle proteolysis and adipose lipolysis, thus creating a prolonged stress-like environment with loss of appetite and increased resting energy expenditure. Recent trials using a monoclonal antibody targeting IL-1β, canakinumab, have shown a potential role in lung cancer; however, a potential role of targeting IL-1β to treat cachexia in patients with lung cancer is unclear, yet the underlying pathophysiology provides a sound rationale that this may be a viable therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.